What is the recommended dosing regimen for eslicarbazepine acetate, including initial dose, titration schedule, maintenance range, and dose adjustments for renal impairment and elderly patients?

Eslicarbazepine Dosing

For adults with focal-onset seizures, initiate eslicarbazepine acetate at 400 mg once daily for 1-2 weeks, then titrate to the maintenance dose of 800-1200 mg once daily; in patients with creatinine clearance <60 mL/min, reduce the starting dose by 50% and titrate more cautiously.

Initial Dosing and Titration

Adults (Standard Renal Function)

• Starting dose: 400 mg once daily 1
• Titration schedule: Increase by 400 mg weekly intervals 2
• Maintenance range: 800-1200 mg once daily 2, 3

The evidence strongly supports starting at 400 mg rather than 800 mg. An integrated analysis of three randomized trials demonstrated that patients initiating at 800 mg once daily experienced significantly higher rates of adverse events in the first week (62% vs 35%) compared to those starting at 400 mg, with notably more dizziness, somnolence, nausea, and headache 1. Initiating at 400 mg for 1-2 weeks is associated with lower discontinuation rates and better tolerability, even when targeting higher maintenance doses 1.

While 800 mg initiation is feasible if immediate seizure reduction is critical, the trade-off is substantially increased early adverse events 1.

Maintenance Dosing

• Optimal efficacy: 800 mg and 1200 mg once daily both demonstrated statistically significant reductions in seizure frequency versus placebo (p=0.0028 and p=0.0003, respectively) 2
• Responder rates: 34% at 800 mg and 43% at 1200 mg (vs 20% placebo) 2
• The 400 mg dose showed minimal benefit over placebo 2

Renal Impairment Adjustments

This is critical: Eslicarbazepine is 66% renally excreted, and clearance is directly dependent on renal function 4, 5.

Dosing by Creatinine Clearance:

• CrCl ≥60 mL/min: Standard dosing as above

• CrCl 30-60 mL/min (mild-moderate impairment):

  • Start at 200-300 mg once daily (50% reduction)
  • Titrate slowly to 400-800 mg once daily
  • AUC increases 35-50% in this population 5

• CrCl <30 mL/min (severe impairment):

  • Start at 200 mg once daily
  • Maximum 600 mg once daily
  • AUC increases up to 60% 5

• End-stage renal disease/hemodialysis:

  • Dose adjustment required; hemodialysis effectively removes metabolites 5
  • Consider post-dialysis supplementation

The pharmacokinetic study showed eslicarbazepine clearance decreased from 3.40 L/h in normal renal function to 1.33 L/h in severe impairment 5. Dose adjustment is mandatory when CrCl <60 mL/min to prevent accumulation and toxicity 4, 5.

Elderly Patients (≥65 Years)

• Starting dose: 400 mg once daily
• Maintenance range: 400-1200 mg once daily (same as younger adults)
• Key consideration: Age-related renal decline is the primary concern 6

In elderly patients, eslicarbazepine was safe and well-tolerated at 400-1200 mg once daily, with 65.3% experiencing treatment-emergent adverse events (most commonly dizziness 12.5%, somnolence 9.7%, and hyponatremia 8.3%) 6. All elderly patients require assessment of creatinine clearance before dosing, as serum creatinine may appear normal despite significant GFR reduction 7, 6.

Elderly-Specific Monitoring:

• Sodium levels: Close monitoring required; hyponatremia occurred in 8.3% of elderly patients 6
• Thyroid function: 33% showed shifts to decreased free T4 (not clinically significant) 6
• Assess CrCl using Cockcroft-Gault equation, not serum creatinine alone 7

Pediatric Dosing (Ages 6-18 Years)

• Starting dose: 10 mg/kg/day once daily
• Maintenance dose: 20-30 mg/kg/day once daily (maximum 1200 mg/day) 8, 3
• Titration: Increase weekly based on response and tolerability

Post hoc analysis suggests patients >6 years old benefit most from 30 mg/kg/day dosing 8. The drug is approved for children ≥6 years as adjunctive therapy 3.

Special Considerations

Hyponatremia Risk

• Occurs in <6% of patients overall 9
• More frequent with monotherapy than adjunctive therapy 9
• Dose-dependent: increases with higher doses 9
• Monitor serum sodium at baseline, during titration, and if symptoms develop (nausea, vomiting, confusion, lethargy) 9
• Most cases occur with sodium ≤125 mEq/L 9

Drug Interactions

• Eslicarbazepine clearance is induced by phenobarbital, phenytoin, and carbamazepine 4
• Decreases oral contraceptive efficacy (use alternative contraception) 4
• Reduces simvastatin exposure 4

Administration

• Once-daily dosing (half-life 20-24 hours supports this) 4
• Can be taken with or without food
• Linear pharmacokinetics at 400-1600 mg/day 4

Common Pitfalls

1. Starting at 800 mg: Dramatically increases early adverse events and discontinuation 1
2. Ignoring renal function in elderly: Age-related GFR decline requires dose adjustment even with "normal" creatinine 7, 6
3. Inadequate sodium monitoring: Hyponatremia can be serious; monitor proactively 9
4. Underdosing: The 400 mg dose is ineffective; target 800-1200 mg for efficacy 2